Efficacy of hydroxyurea in providing transfusion independence in β-thalassemia. (yeni pencere açar)

Ansari SH, Shamsi TS, Ashraf M, Perveen K, Farzana T, Bohray M, Erum S, Mehboob T.

Kaynak‎: J Pediatr Hematol Oncol 2011;33(5):339-43.

İndeks‎: PubMed 21602718

DOI‎: 10.1097/MPH.0b013e31821b0770

https://www.ncbi.nlm.nih.gov/pubmed/21602718 (yeni pencere açar)

Gγ-Xmn I polymorphism: a significant determinant of β-thalassemia treatment without blood transfusion. (yeni pencere açar)

Ansari SH, Shamsi TS, Munzir S, Khan MT, Erum S, Perveen K, Farzana T, Ashraf M, Mehboob T, Moinuddin M.

Kaynak‎: J Pediatr Hematol Oncol 2013;35(4):e153-6.

İndeks‎: PubMed 23389500

DOI‎: 10.1097/MPH.0b013e31827e8662

https://www.ncbi.nlm.nih.gov/pubmed/23389500 (yeni pencere açar)

Efficacy of hydroxyurea (HU) in reduction of pack red cell (PRC) transfusion requirement among children having beta-thalassemia major: Karachi HU trial (KHUT). (yeni pencere açar)

Ansari SH, Shamsi TS, Siddiqui FJ, Irfan M, Perveen K, Farzana T, Panjwani VK, Yousuf A, Mehboob T.

Kaynak‎: J Pediatr Hematol Oncol 2007;29(11):743-6.

İndeks‎: PubMed 17984691

DOI‎: 10.1097/MPH.0b013e318157fd75

https://www.ncbi.nlm.nih.gov/pubmed/17984691 (yeni pencere açar)

Hydroxyurea can eliminate transfusion requirements in children with severe beta-thalassemia. (yeni pencere açar)

Bradai M, Abad MT, Pissard S, Lamraoui F, Skopinski L, de Montalembert M.

Kaynak‎: Blood 2003;102(4):1529-30.

İndeks‎: PubMed 12702505

DOI‎: 10.1182/blood-2003-01-0117

https://www.ncbi.nlm.nih.gov/pubmed/12702505 (yeni pencere açar)

Decreased transfusion needs associated with hydroxyurea therapy in Algerian patients with thalassemia major or intermedia. (yeni pencere açar)

Bradai M, Pissard S, Abad MT, Dechartres A, Ribeil JA, Landais P, de Montalembert M.

Kaynak‎: Transfusion 2007;47(10):1830-6.

İndeks‎: PubMed 17880608

DOI‎: 10.1111/j.1537-2995.2007.01399.x

https://www.ncbi.nlm.nih.gov/pubmed/17880608 (yeni pencere açar)

Hydroxyurea can reduce or eliminate transfusion requirements in children with major and intermediate thalassemia. (yeni pencere açar)

Hashemi A, Abrishamkar M, Jenabzade AR, Eslami Z.

Kaynak‎: Iran J Blood Cancer 2009;1(4):147-50.

İndeks‎: IMEMR 107228

https://www.ijbc.ir/browse.php?a_id=4&sid=1&slc_lang=en (yeni pencere açar)

Genotype-phenotype relationship of patients with β-thalassemia taking hydroxyurea: a 13-year experience in Iran. (yeni pencere açar)

Karimi M, Haghpanah S, Farhadi A, Yavarian M.

Kaynak‎: Int J Hematol 2012;95(1):51-6.

İndeks‎: PubMed 22180324

DOI‎: 10.1007/s12185-011-0985-6

https://www.ncbi.nlm.nih.gov/pubmed/22180324 (yeni pencere açar)

Fetal globin stimulant therapies in the beta-hemoglobinopathies: principles and current potential. (yeni pencere açar)

Perrine SP.

Kaynak‎: Pediatr Ann 2008;37(5):339-46.

İndeks‎: PubMed 18543545

https://www.ncbi.nlm.nih.gov/pubmed/18543545 (yeni pencere açar)

A randomised double-blind placebo-controlled clinical trial of oral hydroxyurea for transfusion-dependent β-thalassaemia. (yeni pencere açar)

Yasara N, Wickramarathne N, Mettananda C, Silva I, Hameed N, Attanayaka K, Rodrigo R, Wickramasinghe N, Perera L, Manamperi A, Premawardhena A, Mettananda S

Kaynak‎: Sci Rep. 2022;12(1):2752.

İndeks‎: PubMed 35177777

DOI‎: 10.1038/s41598-022-06774-8

https://pubmed.ncbi.nlm.nih.gov/35177777/ (yeni pencere açar)

Response to hydroxyurea treatment in Iranian transfusion-dependent beta-thalassemia patients. (yeni pencere açar)

Yavarian M, Karimi M, Bakker E, Harteveld CL, Giordano PC.

Kaynak‎: Haematologica 2004;89(10):1172-8.

İndeks‎: PubMed 15477200

https://www.ncbi.nlm.nih.gov/pubmed/15477200 (yeni pencere açar)

Hydroxyurea therapy in 49 patients with major beta-thalassemia. (yeni pencere açar)

Zamani F, Shakeri R, Eslami SM, Razavi SM, Basi A.

Kaynak‎: Arch Iran Med 2009;12(3):295-7.

İndeks‎: PubMed 19400608

https://www.ncbi.nlm.nih.gov/pubmed/19400608 (yeni pencere açar)

Use of hydroxyurea and recombinant erythropoietin in management of homozygous ß⁰ thalassemia. (yeni pencere açar)

Kohli-Kumar M, Marandi H, Keller MA, Guertin K, Hvizdala E.

Kaynak‎: J Pediatr Hematol Oncol 2002;24(9):777-8.

İndeks‎: PubMed 12468925

https://www.ncbi.nlm.nih.gov/pubmed/12468925 (yeni pencere açar)

Termination of transfusion dependence in beta-thalassemia: two-year experience with recombinant human erythropoietin. (yeni pencere açar)

Nişli G, Kavakli K, Aydinok Y, Oztop S, Cetingül N.

Kaynak‎: Pediatr Hematol Oncol 1997;14(3):285-7.

İndeks‎: PubMed 9185215

https://www.ncbi.nlm.nih.gov/pubmed/9185215 (yeni pencere açar)

Fetal globin gene inducers: novel agents and new potential. (yeni pencere açar)

Perrine SP, Castaneda SA, Chui DH, Faller DV, Berenson RJ, Siritanaratku N, Fucharoen S.

Kaynak‎: Ann N Y Acad Sci 2010;1202:158-64.

İndeks‎: PubMed 20712788

DOI‎: 10.1111/j.1749-6632.2010.05593.x

https://www.ncbi.nlm.nih.gov/pubmed/20712788 (yeni pencere açar)